COSCIENS Biopharma Inc. CSCIF
6.10
0.62
11.31%
as of 25 Sep
- Market cap
- $8.6M
- P/E
- 1.0×
Follow CSCIF
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(118.80%) | (121.84%) | 31.84% | 59.74% | |
| (44.08%) | (36.66%) | 16.22% | 28.24% | ||
ROIC |
0.00% | 0.00% | (51.58%) | (40.56%) | |
Return on Tangible Assets |
(75.50%) | (58.54%) | 23.91% | 40.44% | |
Average Days of Receivables |
68.05 | 61.39 | 90.99 | 99.19 | |
Free Cash Flow per Share |
(10.36) | (8.47) | (8.23) | (3.36) | |
Free Cash Flow |
(10.97) | (8.93) | (8.61) | (3.52) | |
Capital Expenditures |
(0.96) | (0.46) | 0.16 | 0.20 | |
Piotroski F-Score |
4.00 | 2.00 | 4.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
(73.52%) | (76.00%) | (43.15%) | (18.51%) | |
Accounts Receivable Turnover |
4.76 | 4.02 | 4.15 | 3.39 | |
Accounts Payable Turnover |
1.42 | 1.47 | 1.75 | 2.42 | |
Inventory Turnover |
1.90 | 2.43 | 2.77 | 3.36 | |
Average Days of Payables |
147.61 | 141.68 | 68.59 | 62.60 | |
Days of Inventory on Hand |
133.29 | 98.34 | 81.40 | 75.03 | |
Tax Rate |
0.00 | 0.09 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
50.75% | 39.34% | 32.87% | 26.69% | |
Selling, General and Administrative Expense of Revenue |
111.43% | 134.20% | 110.99% | 90.04% | |
Share Based Compensation of Revenue |
(1.05%) | (0.16%) | (0.21%) | 0.78% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.67 | 0.82 | (2.16) | (0.57) | |
Depreciation/Fixed assets |
0.04 | 0.11 | 0.12 | 0.14 | |
Capex/Depreciation |
(2.66) | (0.43) | 0.14 | 0.16 | |
Revenue per Share |
8.13 | 7.11 | 7.64 | 8.33 | |
Operating CF per Share |
(9.45) | (8.03) | (8.38) | (3.56) | |
Capex per Share |
(0.91) | (0.44) | 0.15 | 0.19 | |
Capex to Sales |
0.11 | 0.06 | (0.02) | (0.02) | |
Net Profit Margin |
(173.14%) | (138.14%) | 50.68% | 75.11% |
Columns are period end dates